The Board considered and adopted the financial results for the quarter and year ended March 31, 2026
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Samrat Pharmachem reported a dramatic turnaround from profit to loss. Revenue from operations for FY2026 was ₹28,972 lakhs, marginally up 1.4% from ₹28,586 lakhs in the prior year. However, the company posted a net loss of ₹331.20 lakhs compared to a profit of ₹711.22 lakhs in FY2025 — a swing of over ₹1,042 lakhs. Cost of materials consumed jumped significantly to ₹28,967 lakhs (up ~₹2,040 lakhs), erasing margins. PBT before exceptional items turned negative at ₹298.10 lakhs versus a profit of ₹988.61 lakhs. The auditors issued an unmodified opinion confirming clean financials. Cash position improved to ₹588.24 lakhs from just ₹4.83 lakhs, aided by positive operating cash flow of ₹888 lakhs.
The company has swung into losses despite near-flat revenue, indicating severe margin compression from rising input costs. Shareholders should monitor if this is a cyclical cost issue or structural profitability concern.